Pre-clinical
2024
-
Development and Preclinical Characterization of an Engineered T-Cell Therapy Targeting PRAME-Expressing Solid Tumors, G. Pope et al., ASGCT 27th annual meeting 2024
Presented at the ASGCT 27th Annual Meeting, Baltimore, MD, May 7–11, 2024
2022
-
A Novel Flow Cytometry Method for Rapid Assessment of Lentiviral Detection
PDF poster. ASGCT Annual Meeting. May 16-19, 2022. Washington, DC and virtual
Fraser Wilkes, MS, et al. -
Next-Generation, Inducible IL-7–Expressing, Tumor-Infiltrating Lymphocytes by Lentiviral Vector Genetic Modification for Clinical Application
PDF poster. ASGCT Annual Meeting. May 16-19, 2022. Washington, DC and virtual
Michael Douglas Crowther, PhD, et al. -
IL-7 and CCL19 Expression in Specific Peptide Enhanced Affinity Receptor T-cells Targeting MAGE-A4 Display Improved Survival and Ability to Induce Migration of Immune Cells
PDF poster. ASGCT Annual Meeting. May 16-19, 2022. Washington, DC and virtual
George R. Pope, PhD, et al.
2021
-
Manuscript
Engineering cancer antigen-specific T cells to overcome the immunosuppressive effects of TGF-β.
The Journal of Immunology 2022 Jan 1;208(1):169-180.
Jonathan DS, et al.
PDF upon request.
2020
-
Manuscript
Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy
OncoImmunology. 24 Nov 2019. Joseph P. Sanderson et at.
2018
-
Development of novel cancer immunotherapy by exploring human immunopeptidome using mass spectrometry
PDF poster. Hupo World Congress. Sep. 30-Oct.3, 2018. Orlando, FL.
Kamila Chughtai, PhD, et al. -
Manuscript
Fludarabine and neurotoxicity in engineered T-cell therapy
Gene Therapy 2018;25:175-191.
Lowe KL, et al.
2017
-
Manuscript
Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells.
Clinical & Experimental Immunology 2017;187(1):124-137.
Tan MP, et al.
2013
-
Manuscript
Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells.
Oncoimmunology 2013 September;2(11):e26840.
Bossi G, et al -
Manuscript
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
Blood 2013 August;122(6):863-871.
Linette GP, et al. -
Manuscript
A pharmacologic perspective on newly emerging T-cell manipulation technologies.
British Journal of Clinical Pharmacology 2013 August;76(2):173-187.
Smethurst D.
Allogeneic
2020
-
Driving ADP-A2M4 SPEAR Expression from an Endogenous Hematopoietic Lineage Promotor for “Off-the-Shelf” T-Cell Therapy for MAGE-A4+ Solid Tumors
PDF poster. ASGCT Annual Meeting. May 12-May 15, 2020. Virtual.
Garth Hamilton, PhD, et al.
2019
-
Differentiating T-Cells from hiPSCs to create off-the-shelf SPEAR T-Cell therapies.
PDF presentation. ASGCT Annual Meeting. Apr. 29-May 2, 2019. Washington DC
Lee Carpenter, PhD, et al.
CMC
2023
-
Interview - Ensuring success in working with apheresis centers
Cell & Gene Therapy Insights 2023; 9(2), 141–146 DOI: 10.18609/cgti.2023.019.
Suzanne Kamps
2022
-
Building an integrated vector supply to support autologous cell therapy for solid tumours
European Pharmaceutical Review Volume 27, Issue 05, November 2022.
James Nanista and Josh Hunt
2019
-
Assessing the potency of SPEAR T cells: development and validation of a flow cytometry-based cytotoxicity assay
PDF poster. BEBPA EUR Bioassay Conference. Sep. 25-27, 2019. Prague, Czechia.
Rachel Kenneil, PhD, et al.
HLA Independent TCRs (HiTs)
2024
-
Selection, engineering, and in vivo testing of a human leukocyte antigen–independent T-cell receptor recognizing human mesothelin.
M. Hiscox et al. PLOS ONE 19(4): e0301175. DOI: 10.1371/journal.pone.0301175.
2021
-
In vitro Selection and Engineering of a Human Leukocyte Antigen-Independent T-Cell Receptor (HiT) Recognizing Human Mesothelin
PDF presentation. ASGCT Annual Meeting. May 11-14, 2021. Virtual.
Martyn J. Hiscox, PhD, et al.